Trial Profile
The assessment of factor affecting toxicity of multikinase inhibitor pazopanib in soft tissue sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Pharmacokinetics
- 05 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2015 New trial record